Investigating One Health risks for human colonisation with extended spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Malawian households: a longitudinal cohort study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Oxford] : Elsevier Ltd., [2020]-
    • Subject Terms:
    • Abstract:
      Background: Low-income countries have high morbidity and mortality from drug-resistant infections, especially from enteric bacteria such as Escherichia coli. In these settings, sanitation infrastructure is of variable and often inadequate quality, creating risks of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales transmission. We aimed to describe the prevalence, distribution, and risks of ESBL-producing Enterobacterales colonisation in sub-Saharan Africa using a One Health approach.
      Methods: Between April 29, 2019, and Dec 3, 2020, we recruited 300 households in Malawi for this longitudinal cohort study: 100 each in urban, peri-urban, and rural settings. All households underwent a baseline visit and 195 were selected for longitudinal follow-up, comprising up to three additional visits over a 6 month period. Data on human health, antibiotic usage, health-seeking behaviours, structural and behavioural environmental health practices, and animal husbandry were captured alongside human, animal, and environmental samples. Microbiological processing determined the presence of ESBL-producing E coli and Klebsiella pneumoniae, and hierarchical logistic regression was performed to evaluate the risks of human ESBL-producing Enterobacterales colonisation.
      Findings: A paucity of environmental health infrastructure and materials for safe sanitation was identified across all sites. A total of 11 975 samples were cultured, and ESBL-producing Enterobacterales were isolated from 1190 (41·8%) of 2845 samples of human stool, 290 (29·8%) of 973 samples of animal stool, 339 (66·2%) of 512 samples of river water, and 138 (46·0%) of 300 samples of drain water. Multivariable models illustrated that human ESBL-producing E coli colonisation was associated with the wet season (adjusted odds ratio 1·66, 95% credible interval 1·38-2·00), living in urban areas (2·01, 1·26-3·24), advanced age (1·14, 1·05-1·25), and living in households where animals were observed interacting with food (1·62, 1·17-2·28) or kept inside (1·58, 1·00-2·43). Human ESBL-producing K pneumoniae colonisation was associated with the wet season (2·12, 1·63-2·76).
      Interpretation: There are extremely high levels of ESBL-producing Enterobacterales colonisation in humans and animals and extensive contamination of the wider environment in southern Malawi. Urbanisation and seasonality are key risks for ESBL-producing Enterobacterales colonisation, probably reflecting environmental drivers. Without adequate efforts to improve environmental health, ESBL-producing Enterobacterales transmission is likely to persist in this setting.
      Funding: Medical Research Council, National Institute for Health and Care Research, and Wellcome Trust.
      Translation: For the Chichewa translation of the abstract see Supplementary Materials section.
      Competing Interests: Declaration of interests We declare no competing interests.
      (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
    • References:
      Nature. 2016 May 11;533(7602):212-6. (PMID: 27172044)
      Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702)
      Wellcome Open Res. 2019 Oct 23;4:160. (PMID: 31976380)
      Glob Health Action. 2019;12(1):1639388. (PMID: 31339473)
      Nat Microbiol. 2022 Apr;7(4):581-589. (PMID: 35288654)
      One Health. 2021 Jan 26;12:100220. (PMID: 33644290)
      J Clin Microbiol. 2019 May 24;57(6):. (PMID: 30944193)
      Lancet. 2016 Jan 9;387(10014):176-87. (PMID: 26603922)
      Lancet Infect Dis. 2018 Mar;18(3):318-327. (PMID: 29276051)
      Am J Trop Med Hyg. 2019 Aug;101(2):294-303. (PMID: 31237230)
      Antimicrob Resist Infect Control. 2021 Jan 22;10(1):18. (PMID: 33482919)
      Antibiotics (Basel). 2021 Apr 30;10(5):. (PMID: 33946277)
      Trans R Soc Trop Med Hyg. 2016 Jul;110(7):377-80. (PMID: 27475987)
      Lancet Planet Health. 2019 Aug;3(8):e357-e369. (PMID: 31439317)
      Antibiotics (Basel). 2022 Jan 17;11(1):. (PMID: 35052997)
      Lancet Microbe. 2022 Dec;3(12):e922-e930. (PMID: 36335953)
      Front Vet Sci. 2022 May 24;9:876513. (PMID: 35685344)
      PLOS Glob Public Health. 2022 Jun 8;2(6):e0000314. (PMID: 36962375)
      Int J Environ Res Public Health. 2020 Jun 23;17(12):. (PMID: 32585833)
      Environ Health Perspect. 2021 Feb;129(2):27007. (PMID: 33617318)
      Wellcome Open Res. 2023 May 2;7:55. (PMID: 38817338)
      Nat Microbiol. 2020 Jun;5(6):787-795. (PMID: 32467623)
      Sci Rep. 2018 Jan 18;8(1):1114. (PMID: 29348433)
      Sci Rep. 2021 Jan 22;11(1):2091. (PMID: 33483551)
      Int J Environ Res Public Health. 2017 Apr 06;14(4):. (PMID: 28383517)
    • Grant Information:
      MR/S004793/1 United Kingdom MRC_ Medical Research Council; United Kingdom WT_ Wellcome Trust
    • Accession Number:
      EC 3.5.2.6 (beta-Lactamases)
      0 (Anti-Infective Agents)
    • Publication Date:
      Date Created: 20230519 Date Completed: 20230710 Latest Revision: 20240921
    • Publication Date:
      20240921
    • Accession Number:
      PMC10319635
    • Accession Number:
      10.1016/S2666-5247(23)00062-9
    • Accession Number:
      37207684